APA (7th ed.) Citation

Price, D., Henley, W., Cançado, J. E. D., Fabbri, L. M., Kerstjens, H. A., Papi, A., . . . Georges, G. (2024). Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS. Pragmatic & Observational Research, 15, 1. https://doi.org/10.2147/POR.S438031

Chicago Style (17th ed.) Citation

Price, David, et al. "Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate Versus Patients Initiating LABD Without ICS." Pragmatic & Observational Research 15 (2024): 1. https://doi.org/10.2147/POR.S438031.

MLA (9th ed.) Citation

Price, David, et al. "Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate Versus Patients Initiating LABD Without ICS." Pragmatic & Observational Research, vol. 15, 2024, p. 1, https://doi.org/10.2147/POR.S438031.